ATE200027T1 - Tetrahydrolipstatin enthaltende präparate - Google Patents

Tetrahydrolipstatin enthaltende präparate

Info

Publication number
ATE200027T1
ATE200027T1 AT98905346T AT98905346T ATE200027T1 AT E200027 T1 ATE200027 T1 AT E200027T1 AT 98905346 T AT98905346 T AT 98905346T AT 98905346 T AT98905346 T AT 98905346T AT E200027 T1 ATE200027 T1 AT E200027T1
Authority
AT
Austria
Prior art keywords
preparations containing
tetrahydrolipstatin
containing tetrahydrolipstatin
preparations
Prior art date
Application number
AT98905346T
Other languages
English (en)
Inventor
Navnit Hargovindas Shah
Max Zeller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26671373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200027(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE200027T1 publication Critical patent/ATE200027T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98905346T 1997-02-05 1998-01-24 Tetrahydrolipstatin enthaltende präparate ATE200027T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3738497P 1997-02-05 1997-02-05
US09/003,137 US6004996A (en) 1997-02-05 1998-01-06 Tetrahydrolipstatin containing compositions
PCT/EP1998/000395 WO1998034607A1 (en) 1997-02-05 1998-01-24 Tetrahydrolipstatin containing compositions

Publications (1)

Publication Number Publication Date
ATE200027T1 true ATE200027T1 (de) 2001-04-15

Family

ID=26671373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98905346T ATE200027T1 (de) 1997-02-05 1998-01-24 Tetrahydrolipstatin enthaltende präparate

Country Status (29)

Country Link
US (1) US6004996A (de)
EP (1) EP0921796B1 (de)
CN (1) CN1193752C (de)
AR (1) AR010704A1 (de)
AT (1) ATE200027T1 (de)
AU (1) AU713192B2 (de)
CA (1) CA2258095C (de)
CO (1) CO4920214A1 (de)
CY (1) CY2264B1 (de)
CZ (1) CZ287154B6 (de)
DE (1) DE69800639T2 (de)
DK (1) DK0921796T3 (de)
ES (1) ES2156028T3 (de)
GR (1) GR3036064T3 (de)
HR (1) HRP980057B1 (de)
HU (1) HU225035B1 (de)
ID (1) ID26509A (de)
IL (1) IL126902A (de)
MA (1) MA24466A1 (de)
MY (1) MY118371A (de)
NO (1) NO320445B1 (de)
NZ (1) NZ332659A (de)
PE (1) PE57599A1 (de)
PT (1) PT921796E (de)
RU (1) RU2170579C2 (de)
SI (1) SI0921796T1 (de)
UY (1) UY24875A1 (de)
WO (1) WO1998034607A1 (de)
YU (1) YU49423B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU34199A (sh) * 1997-02-05 2002-08-12 F. Hoffmann-La Roche Ag. Primena inhibitora gastrointestinalne lipaze
WO2000009122A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
NZ510311A (en) * 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (de) 2000-03-06 2001-09-12 Vernalis Research Limited Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
YU96602A (sh) * 2000-06-27 2005-03-15 F.Hoffmann-La Roche Ag. Postupak za spravljanje smeše
PT1307264E (pt) 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
MXPA03000694A (es) * 2000-07-28 2003-06-04 Hoffmann La Roche Nuevo uso de los inhibidores de lipasa.
ATE390920T1 (de) 2000-08-09 2008-04-15 Hoffmann La Roche Lipase inhibitoren zur behandlung von dyspepsia
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
ATE403647T1 (de) 2000-10-16 2008-08-15 Hoffmann La Roche Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EP1347979B1 (de) 2000-12-27 2007-08-08 F. Hoffmann-La Roche Ag Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
BR0209957A (pt) * 2001-05-21 2004-03-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
EP1448169A1 (de) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Methode zur verbesserung der löslichkeit von schwer-dispergierbaren medikamenten
US20050118258A1 (en) * 2001-12-20 2005-06-02 Federico Shroppolo Pharmaceutical composition comprising skim milk powder
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
EP1480976B1 (de) 2002-02-28 2007-09-19 F.Hoffmann-La Roche Ag Thiazolderivate als npy-rezeptorantagonisten
WO2003090742A1 (en) * 2002-04-26 2003-11-06 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a lipase inhibitor and glucomannan
KR100647932B1 (ko) * 2002-07-05 2006-11-23 에프. 호프만-라 로슈 아게 퀴나졸린 유도체
RU2324685C2 (ru) * 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
ATE345340T1 (de) * 2002-09-12 2006-12-15 Hoffmann La Roche N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
BR0316556A (pt) * 2002-11-25 2005-10-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
BRPI0413500A (pt) * 2003-08-12 2006-10-10 Hoffmann La Roche compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
EP1656374B1 (de) * 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazolderivate als npy-antagonisten
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006117304A1 (en) * 2005-05-03 2006-11-09 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
AU2006281435A1 (en) * 2005-08-18 2007-02-22 F. Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as H3 receptor modulators
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
JP2009517434A (ja) * 2005-11-30 2009-04-30 エフ．ホフマン−ラ ロシュ アーゲー ５−置換インドール−２−カルボキサミド誘導体
BRPI0619266A2 (pt) * 2005-11-30 2011-09-27 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, obesidade, diabetes do tipo ii e seu uso
CA2630314A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
DE602006010433D1 (de) * 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
WO2007068620A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
CA2631695A1 (en) * 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyridine derivatives as h3 receptor modulators
EP1803714A1 (de) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung kristalliner Formen von Orlistat
KR20080085031A (ko) * 2006-01-13 2008-09-22 에프. 호프만-라 로슈 아게 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 ｈ3수용체 조절제로서의 이의 용도
EP1979322B1 (de) * 2006-01-23 2010-09-01 F. Hoffmann-La Roche AG Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007137955A1 (en) * 2006-05-30 2007-12-06 F. Hoffmann-La Roche Ag Piperidinyl pyrimidine derivatives
EP1872777A1 (de) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung enthaltend Tetrahydrolipstatin
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
BRPI0817053A2 (pt) * 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
MX342962B (es) 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101731155B1 (ko) * 2011-06-15 2017-04-27 신톤 비.브이. 안정화된 보리코나졸 조성물
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
CN102362863B (zh) * 2011-11-21 2013-06-12 山东新时代药业有限公司 一种含奥利司他的制剂及其制备方法
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
AU2012101841A4 (en) * 2011-12-23 2013-01-17 Norgine Bv Compositions comprising cetilistat
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
IN2014MN01933A (de) * 2012-03-13 2015-07-10 Piramal Entpr Ltd
EP2919772B1 (de) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitoren und leucin oder ein leucin metabolit zur behandlung von diabetes
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
CN104740637A (zh) * 2013-12-31 2015-07-01 北京科信必成医药科技发展有限公司 一种稳定的奥利司他口服制剂及其制备方法
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2017192921A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN108785272B (zh) * 2018-09-04 2019-04-09 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
EP4422607A4 (de) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc Orale und nasale zusammensetzungen und behandlungsverfahren
CN115300479A (zh) * 2022-08-23 2022-11-08 宁波高新区美诺华医药创新研究院有限公司 奥利司他胶囊制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor

Also Published As

Publication number Publication date
DE69800639T2 (de) 2001-10-31
SI0921796T1 (en) 2001-06-30
AU6097298A (en) 1998-08-26
CY2264B1 (en) 2003-07-04
NZ332659A (en) 2000-03-27
CO4920214A1 (es) 2000-05-29
YU49698A (sh) 1999-09-27
HK1021313A1 (en) 2000-06-09
NO985337L (no) 1998-11-16
IL126902A (en) 2002-12-01
CA2258095A1 (en) 1998-08-13
PT921796E (pt) 2001-09-28
CA2258095C (en) 2000-02-22
RU2170579C2 (ru) 2001-07-20
US6004996A (en) 1999-12-21
MY118371A (en) 2004-10-30
UY24875A1 (es) 2000-12-29
DK0921796T3 (da) 2001-07-16
IL126902A0 (en) 1999-09-22
CZ352898A3 (cs) 1999-02-17
HU225035B1 (en) 2006-05-29
DE69800639D1 (de) 2001-05-03
AR010704A1 (es) 2000-06-28
MA24466A1 (fr) 1998-10-01
CZ287154B6 (en) 2000-09-13
NO320445B1 (no) 2005-12-05
HU0001468D0 (en) 2000-05-28
YU49423B (sh) 2006-01-16
HRP980057A2 (en) 1998-12-31
PE57599A1 (es) 1999-06-11
EP0921796A1 (de) 1999-06-16
WO1998034607A1 (en) 1998-08-13
HUP0001468A3 (en) 2000-12-28
ES2156028T3 (es) 2001-06-01
CN1220600A (zh) 1999-06-23
HUP0001468A2 (hu) 2000-09-28
NO985337D0 (no) 1998-11-16
ID26509A (id) 2001-01-11
PL330972A1 (en) 1999-06-21
GR3036064T3 (en) 2001-09-28
AU713192B2 (en) 1999-11-25
EP0921796B1 (de) 2001-03-28
CN1193752C (zh) 2005-03-23
HRP980057B1 (en) 2001-08-31

Similar Documents

Publication Publication Date Title
ATE200027T1 (de) Tetrahydrolipstatin enthaltende präparate
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
DE69839157D1 (de) Fullurene enthaltendes katherdersystem
DE69802187D1 (de) Mullit enthaltende schleifgegenstände
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69831486D1 (de) Antiproliferative zubereitungen
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
DE69832623D1 (de) Mikrogefertigte kreisel
NO20001776L (no) Medikamenter
NO995712D0 (no) Oftalmiske preparater
ATE266383T1 (de) Dermatologische zubereitungen
DE59804418D1 (de) Kosmetische zubereitungen
DE69825622D1 (de) Schweisshemmende deodorierende präparate
DE59407063D1 (de) Deodorierende zubereitungen
ATE281836T1 (de) Stabilisierte tibolone zubereitungen
DE59707298D1 (de) Desodorierende zubereitungen
DE69429514D1 (de) Antiparasitäre präparate
FI973171A0 (fi) Foerfarande foer drift av arbetsfartyg
ATE246494T1 (de) Brausezubereitungen
ATE283706T1 (de) ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
DK0826679T3 (da) Naphthylforbindelser og -præparater
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
NO985084D0 (no) Vial
FI964040A7 (fi) Kirjekuori

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification